Final results of a Phase II trial of combined fludarabine (Fludara, Berlex) and alemtuzumab (Campath, Berlex) in patients with chronic lymphocytic leukemia (CLL) show high overall response rates (OR) with excellent overall survival (OS) and time-to-progression (TTP), according to Andreas Engert, Department of Hematology, University of Cologne, Cologne, Germany.
Go to Previous Page
Go to Next Page